Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The reports are tied to Global. The first report grouped here was at 21 Oct 2026, 23:54 UTC. The headline in use is “Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.